- Home
- SNCY vs GOSS Comparison
SNCY vs GOSS Comparison
Compare SNCY & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | GOSS |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.5M | 615.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SNCY | GOSS |
|---|---|---|
| Price | $21.19 | $2.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $19.00 | $8.83 |
| AVG Volume (30 Days) | 1.5M | ★ 5.5M |
| Earning Date | 02-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $1,126,769,000.00 | $44,051,000.00 |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $9.00 | $6.41 |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $8.10 | $0.76 |
| 52 Week High | $22.29 | $3.87 |
Technical Indicators
Market Signals| Indicator | SNCY | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 74.52 | 39.85 |
| Support Level | $20.07 | $2.24 |
| Resistance Level | $22.04 | $2.41 |
| Average True Range (ATR) | 1.01 | 0.22 |
| MACD | 0.18 | -0.00 |
| Stochastic Oscillator | 79.48 | 21.85 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.